KR20210022065A - 암을 치료하는 데 사용하기 위한 lif 억제제와 백금-기반 항신생물제의 조합 - Google Patents

암을 치료하는 데 사용하기 위한 lif 억제제와 백금-기반 항신생물제의 조합 Download PDF

Info

Publication number
KR20210022065A
KR20210022065A KR1020217001441A KR20217001441A KR20210022065A KR 20210022065 A KR20210022065 A KR 20210022065A KR 1020217001441 A KR1020217001441 A KR 1020217001441A KR 20217001441 A KR20217001441 A KR 20217001441A KR 20210022065 A KR20210022065 A KR 20210022065A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
lif
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217001441A
Other languages
English (en)
Korean (ko)
Inventor
호안 세오안 수아레즈
후디트 아니도 폴구에이라
로빈 매튜 홀레트
파트리샤 앤 깁린
잔느 마그람
나이미시 판디아
로버트 와서만
앵거스 싱클레어
Original Assignee
메디뮨 리미티드
펀다시오 프리바다 인스티튜시오 카탈라나 드 르세르카 아이 에스투디스 아반카츠
펀다시오 프리바다 인스티튜트 드인베스티가시오 온콜로지카 데 발 헤브론
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 리미티드, 펀다시오 프리바다 인스티튜시오 카탈라나 드 르세르카 아이 에스투디스 아반카츠, 펀다시오 프리바다 인스티튜트 드인베스티가시오 온콜로지카 데 발 헤브론 filed Critical 메디뮨 리미티드
Publication of KR20210022065A publication Critical patent/KR20210022065A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217001441A 2018-06-18 2019-06-17 암을 치료하는 데 사용하기 위한 lif 억제제와 백금-기반 항신생물제의 조합 Ceased KR20210022065A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382432 2018-06-18
EP18382432.5 2018-06-18
PCT/IB2019/000812 WO2019243900A2 (en) 2018-06-18 2019-06-17 Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer

Publications (1)

Publication Number Publication Date
KR20210022065A true KR20210022065A (ko) 2021-03-02

Family

ID=62837845

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217001441A Ceased KR20210022065A (ko) 2018-06-18 2019-06-17 암을 치료하는 데 사용하기 위한 lif 억제제와 백금-기반 항신생물제의 조합

Country Status (12)

Country Link
US (1) US20210187106A1 (cg-RX-API-DMAC7.html)
EP (1) EP3806899A2 (cg-RX-API-DMAC7.html)
JP (2) JP7379390B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210022065A (cg-RX-API-DMAC7.html)
CN (1) CN112955178B (cg-RX-API-DMAC7.html)
AU (2) AU2019291307B2 (cg-RX-API-DMAC7.html)
CA (1) CA3103369A1 (cg-RX-API-DMAC7.html)
EA (1) EA202092964A1 (cg-RX-API-DMAC7.html)
IL (1) IL279444A (cg-RX-API-DMAC7.html)
MA (1) MA52300A (cg-RX-API-DMAC7.html)
SG (1) SG11202012576QA (cg-RX-API-DMAC7.html)
WO (1) WO2019243900A2 (cg-RX-API-DMAC7.html)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
AU2015314980A1 (en) * 2014-09-10 2017-03-02 The Regents Of The University Of California Targeting K-Ras-mediated signaling pathways and malignancy by anti-hLIF antibodies
CA2983126A1 (en) 2015-04-17 2016-10-20 Morphotek, Inc. Methods for treating lung cancer
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
EP3794031A2 (en) * 2018-05-14 2021-03-24 MedImmune Limited Antibodies against lif and dosage forms thereof

Also Published As

Publication number Publication date
CN112955178A (zh) 2021-06-11
JP7603772B2 (ja) 2024-12-20
JP2024023212A (ja) 2024-02-21
JP7379390B2 (ja) 2023-11-14
MA52300A (fr) 2021-04-21
EP3806899A2 (en) 2021-04-21
WO2019243900A3 (en) 2020-03-05
AU2019291307B2 (en) 2024-04-04
JP2021533084A (ja) 2021-12-02
AU2024204564A1 (en) 2024-07-18
CN112955178B (zh) 2025-03-11
WO2019243900A2 (en) 2019-12-26
US20210187106A1 (en) 2021-06-24
EA202092964A1 (ru) 2021-03-30
CA3103369A1 (en) 2019-12-26
AU2019291307A1 (en) 2021-02-04
IL279444A (en) 2021-01-31
SG11202012576QA (en) 2021-01-28

Similar Documents

Publication Publication Date Title
US10583191B2 (en) Antibodies against LIF and uses thereof
US20230042095A1 (en) Antibodies against lif and uses thereof
JP2024160301A (ja) Lifに対する抗体及びそれらの投与形態
JP7603772B2 (ja) 癌の治療に使用するためのlif阻害剤と白金系抗悪性腫瘍剤の組み合わせ
HK40107591A (en) Antibodies against lif and uses thereof
HK40056275A (en) Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer
HK40042216A (en) Antibodies against lif and dosage forms thereof
HK40040276B (en) Antibodies against lif and uses thereof
EA051297B1 (ru) Антитела к lif и их применения
HK40016422B (en) Antibodies against lif and uses thereof
HK40016422A (en) Antibodies against lif and uses thereof
EA045781B1 (ru) Антитела к lif и их применения

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601